AIMS: To determine the efficacy of measuring the transcutaneous bilirubin as a screening tool for clinically significant hyperbilirubinaemia in Indian infants.
N eonatal jaundice or hyperbilirubinemia is a fairly common problem encountered in the newborn nursery. Complications of hyperbilirubinemia, namely, acute bilirubin encephalopathy and/or kernicterus are rare in infants having bilirubin levels below the 95 th percentile. Kernicterus, which was believed to have disappeared almost completely, is now of greater concern for neonatologists and pediatricians because the earlier discharge from the hospital of mothers and neonates prevents an adequate and effective monitoring of jaundice. [1, 2] The problem is that most infants are now being discharged before the age of 48 h whereas their bilirubin levels peak almost always between 3 and 7 days of age. [3] Even though visual evaluation of neonates for jaundice is a time-honored method having certain advantages, the disadvantages are that the correlation with total serum bilirubin (TSB) is poor, even when it is performed by experienced nursery personnel. The revised American Academy of Pediatrics guidelines [4] which have been recently laid down for the prevention and management of hyperbilirubinemia emphasize the importance of an objective assessment of bilirubin status for all neonates before being discharged from the hospitals, and the use of a transcutaneous device is well considered to be an option for this determination. In addition, the guidelines also recommended that "if there is any doubt about the degree of jaundice, the TSB or transcutaneous bilirubin (TcB) should be measured." As TSB estimation is painful, a convenient accurate and noninvasive TcB measurement would be of enormous benefit to physicians, infants, and families.
Previous studies of TcB have produced results which were conflicting with some investigators emphasizing the limitation of this technique [5] and others on the other extreme side of the spectrum reporting that TcB is reliable enough to completely replace laboratory measurement of TSB. [6, 7] Aims and objectives 1 
Total serum bilirubin measurement
TSB estimation was done by modified diazo method on the ROCHE INTEGRA-e 411+ autoanalyzer (mg/dl). This is a routine procedure which is performed regularly in the Biochemistry Department of Institute of Child Health. The assays used by this machine were previously studied by comparing with the gold standard bilirubin measurement of high-performance liquid chromatography (HPLC), and they were found to correlate well. [8] In addition, there was one study which compared HPLC, modified diazo reaction, and TcB measurement and found good correlation among all three methods. [9] Transcutaneous bilirubin measurement For TcB measurement, we used the Jaundice Meter JM-103 device (manufactured by Draeger Medical Systems, Inc., Lubeck, Germany). All the measurements were performed with a single Jaundice Meter JM-103 device in accordance with the manufactures' recommendations. The device is housed in the form of a handheld assembly which has a fiber-optic probe that is placed strategically which allows for a convenient application to the forehead or sternum of the infant. Once the appropriate skin application is established, the light source is triggered and the measured values appear on display.
In this study, TcB measurements were done on sternum within 15 min of TSB measurements. Averaging five readings, computed automatically by the Jaundice Meter when the desired number of measurements is set, provides more precise TcB measurement than using a single measurement. The device does not require user calibration. However, the system includes a checker that measures the intensity of light from the device to ensure the light output is acceptable for proper use.
Risk level determination
We divided the bilirubin level into two groups, namely, "clinically significant jaundice" and "nonclinically significant jaundice" based on the bilirubin nomogram which was developed by Bhutani et al. [7] The bilirubin nomogram plots the age in hours versus the TSB. As the level of bilirubin varies normally with the age, this nomogram thus helps to determine whether an infant is at risk for developing clinically significant hyperbilirubinemia based on the bilirubin levels at a particular hour of life. If a bilirubin value is found to be higher than the 95 th percentile for age curve, the nomogram predicts that the infant is in the "high-risk zone" for developing clinically significant hyperbilirubinemia. Similarly, bilirubin values between the 75 th and 95 th percentile curves predict the infant is in the "high-intermediate risk zone."
The TSB and the average TcB values which were obtained for each infant were plotted on this nomogram. Since both the TSB and TcB values for each individual infant were obtained simultaneously, the same exact hour of life was used to plot both values. For clinically significance, TSB the TcB being higher than the TSB. Majority of the data points fall within ± 1.96 times of the standard deviation (SD) of the difference between TSB and TcB values. This corroborates that there is strong values which were above the 95 th percentile and TcB values which were above the 75 th percentile were used by us.
All bilirubin samples were obtained during the ages of life which are included in the nomogram (0-144 h old).
Results and Analysis
In this study, 100 neonates were enrolled, out of 59 were male and 41 were female. Demographic data such as gestational age, birth weight, and postnatal age are listed in Table 1 . The study group was divided into term group (55 neonates) and preterm group (45 neonates) as explained in Table 2 . Majority of the study participants (55%) were at term at birth [ Table 3 ].
• TSB values ranged from 4.92 to 20.82 mg/dl, with 51% of neonates below the 75 th percentile for age, 19% with levels between 75 th and 95 th percentiles for age, and 30% with levels above the 95 th for age [ Table 4 ] • 26% of the study participants were low birth weight,
i.e below 2500gm [ Table 5 Figure 3 , it was found that the same correlation was present between TcB and TSB in term population as it also was in whole population. From Figure 6 , it was noted that the agreement was same as in whole population and term population. Majority of the data points fall within ± 1.96 times of the SD of the difference between TSB and TcB values. This corroborates that there is strong agreement present. This agreement is also assessed quantitatively by calculating interclass correlation coefficient. This comes to 0.871 with 95% CI of 0.452-0.952. • Sensitivity of the test is 100%, specificity is 72.8%, positive predictive value is 61.2%, and negative predictive value is 100%. None of the 51 neonates with TcB below the 75 th percentile for age had clinically significant hyperbilirubinemia (TSB above the 95 th percentile for the age).
• Figure 7 shows the 3 zones of risk according to TSB vs age Showing that the high risk zone is above 95th centile.
Discussion
According to Rubaltelli et al., [10] it is pertinent to remember that the TSB represents a measurement of the circulating bilirubin while TcB is a measurement of the tissue bilirubin.
As per our present study results in Indian population as in other ethnic groups, the TcB level correlated well with the laboratory measurement of TSB. In the present study, overall correlation of TSB to TcB was found to be linear and statistically significant (r = 0.94, P ≤ 0.001). Similar regression statistics were evident in subset population categorized by gestational age (term r = 0.94, P ≤ 0.001 and preterm r = 0.92, P ≤ 0.001). This is in agreement with the previous studies.
The present study demonstrated that using TcB level which was higher than the 75 th percentile for age was found to be 100% sensitive in identifying infants who might be at risk for developing clinically significant hyperbilirubinemia. None of the neonates with TSB higher than the 95th percentile had a TcB measurement which was <75 th percentile [ Table 8 ]. This is in agreement with the study done by Bhutani et al. [9] In one study, Engle el al. [6] reported a similar correlation between TcB and TSB in preterm and term infants with a correlation coefficient r = 0.77 (n = 121; P < 0.001).
Maisels et al. [11] reported that TcB provided good agreement with laboratory determination of TSB with correlation coefficient r ≥ 0.90 in an essentially Caucasian population. Our present study also showed good correlation between TcB and TSB values with correlation coefficient r = 0.94.
Similar to previous studies, a significant correlation was observed between TSB values. However, as pointed out by Bland and Altman, [12] correlation coefficient could be a poor indicator of the agreement between two clinical tests, and a far better measure of agreement would be the plot of differences of values obtained by the two methods vis-a-vis the mean of the values. Analysis of our results using the Bland-Altman plot, the bias line indicates that difference of 1.2 mg/dl between average We estimated serum bilirubin in the current study in our clinical laboratory whereas previous studies that had evaluated transcutaneous bilirubinometer used HPLC as gold standard. However, Bhutani et al. [9] in their recent report showed that agreement between TcB values and TSB determined by a variety of laboratory methods was comparable to the agreement between TcB and HPLC. Our laboratory performs approximately 2000 total bilirubin estimations monthly, maintaining rigorous quality control standards for bilirubin testing. The results of the present study thus recommend the use of the TcB measurement as a first-line screening tool for hyperbilirubinemia. For infants having a TcB level below the 75 th percentile for age, it could be safely assumed that the infant has a low risk of developing clinically significant hyperbilirubinemia eliminating the need for further testing. In our NICU, where every newborn is routinely required to have a TSB level checked before discharge, this would facilitate the reduction in the number of measurements and hence a potentially painful blood draw.
The present study was not without limitations. First, a small number of neonates were included in this study. Second, different operators obtained the measurements even though we used the same JM-103 device for measuring the TcB for all cases (possibilities of introducing error). Third, our neonates being mostly referred cases from the different hospitals had relatively high levels of jaundice (leading to possible selection bias).
The two methods (TSB and TcB) do not in fact measure the same parameter. Even though the laboratory method measures only that component of bilirubin that is circulating in the blood, the amount of bilirubin that has shifted from the serum into the tissues is quantified by TcB.
If this indicated the serum bilirubin levels that were also available to move into the brain tissue, which being our real concern, then it could offer additional information from which clinical management decisions could be made. These unanswered questions, along with the effects of exchange transfusion and phototherapy on TcB measurement, the effect of drugs as also the accuracy in very low birth weight neonates, and neonates <30 weeks' gestational age, all require further studies.
Conclusion
The results of this study support the use of the transcutaneous bilirubin meter as a screening tool for clinically significant hyperbilirubinemia in Indian infants. The advantage of the TcB meter was that it had an excellent sensitivity, thus making it extremely improbable that an infant with a significant level of hyperbilirubinemia would miss detection with TcB measurement. Even though the specificity of the TcB level was 72%, the test was successfully able to identify a sizeable group of infants who did not need invasive testing for the evaluation of hyperbilirubinemia. As per our study results, we can recommend that all normal infants be screened for hyperbilirubinemia initially by measuring their TcB levels. If the results indicate a TcB level above the 75 th percentile for age, it could then warrant for TSB level estimations.
However, substituting the TcB for TSB as a universal screening tool should await the results of a well-conducted clinical trial for both efficacy as well as cost-effectiveness with the goals of reduction in the hospital readmission rates and the subsequent risks of bilirubin-related neurological sequelae. The clinical value of TcB measurement will evolve over the coming years, not only with continuing technological developments but also with our gradual understanding of the complex relationships existing between accumulation of bilirubin and levels of albumin-bound and unbound bilirubin in both intravascular and extravascular spaces.
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